WHO Drug Information, Vol 34, No. 4, 2020 ATC/DDD Classification

ATC/DDD Classification (Temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2020.

Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2021. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2022 version of the ATC/DDD Index.

New ATC 5th level codes:

ATC level name/INN ATC code abametapir P03AX07 abrocitinib D11AH08 aducanumab N06DX03 ammonia (13N) V09GX05 anifrolumab L04AA51 artemisinin and naphthoquine P01BF08 artemisinin and piperaquine P01BF07 artesunate, sulfadoxine and pyrimethamine P01BF09 asciminib L01EA06 belumosudil L04AA48 berotralstat B06AC06 bevacizumab S01LA08 bimekizumab L04AC21 cefixime and ornidazole J01RA15 cetirizine S01GX12 chloroquine and proguanil P01BB52 clascoterone D10AX06 covid-19 vaccines J07BX03 daprodustat B03XA07 deutetrabenazine N07XX16

917 ATC/DDD Classification WHO Drug Information, Vol 34, No. 4, 2020

diroximel fumarate L04AX09 eptinezumab N02CD05 evinacumab C10AX17 fosdenopterin A16AX19 gallium (68Ga) PSMA-11 V09IX14 haemophilus influenza B, combinations with meningococcus J07AG54 C,Y, conjugated imeglimin A10BX15 lasmiditan N02CC08 lemborexant N05CM21 levamlodipine C08CA17 lonafarnib A16AX20 lumateperone N05AD10 maralixibat chloride A05AX04 metformin, linagliptin and empagliflozin A10BD27 metronidazole and diloxanide P01AB52 netakimab L04AC20 norfloxacin and metronidazole J01RA14 odevixibat A05AX05 ofatumumab L04AA52 oteseconazole J02AC06 pamiparib L01XK06 peficitinib L04AA49 pegunigalsidase alfa A16AB20 ponesimod L04AA50 pralsetinib L01EX23 pravastatin and ezetimibe C10BA11 prolgolimab L01XC42 remdesivir J05AB16 rimegepant N02CD06 ripasudil S01EX07 selpercatinib L01EX22 setmelanotide A08AA12 sodium phosphate V03AG05

918 WHO Drug Information, Vol 34, No. 4, 2020 ATC/DDD Classification sotorasib L01XX73 tanezumab N02BG12 tazemetostat L01XX72 tegoprazan A02BC09 teprotumumab L04AA53 tezepelumab R03DX11 tilbroquinol and tiliquinol P01AA30 tilidine and naloxone N02AX51 trafermin D03AX15 trilaciclib V03AF12 ubrogepant N02CD04 vadadustat B03XA08 viltolarsen M09AX12 volanesorsen C10AX18 vosoritide M05BX07 voxelotor B06AX03

Change of ATC level codes:

ATC level names Previous ATC-code New ATC code and name diphenhydramine R06AA021 R06AA11 dimenhydrinate

1: Splitting of ATC code. Products containing dimenhydrinate (rINN)/diphenhydramine teoclate are moved to the new code. Product containing diphenhydramine chloride will remain in R06AA02.

Change of ATC level names:

ATC code Previous ATC-level name New ATC-level name J02AC triazole derivatives triazole and tetrazole derivatives P01AB51 metronidazole, combinations metronidazole and furazolidone P01BB51 proguanil, combinations proguanil and atovaquone

919 ATC/DDD Classification WHO Drug Information, Vol 34, No. 4, 2020

New DDDs:

ATC level name/INN DDD unit Adm.R ATC code abemaciclib 0.3 g O L01EF03 acalabrutinib 0.2 g O L01EL02 afatinib 40 mg O L01EB03 alectinib 1.2 g O L01ED03 alpelisib 0.3 g O L01EM03 amisulpride 7.5 mg P N05AL05 avapritinib 0.3 g O L01EX18 axitinib 10 mg O L01EK01 binimetinib 90 mg O L01EE03 bosutinib 0.4 g O L01EA04 brigatinib 0.18 g O L01ED04 cabozantinib 60 mg O L01EX07 cannabidiol 0.7 g O N03AX24 capmatinib 0.8 g O L01EX17 ceritinib 0.45 g O L01ED02 cobimetinib 45 mg O L01EE02 copanlisib 6.43 mg O L01EM02 crizotinib 0.5 g O L01ED01 dabrafenib 0.3 g O L01EC02 dacomitinib 45 mg O L01EB07 darolutamide 1.2 g O L02BB06 dasatinib 0.1 g O L01EA02 duvelisib 50 mg O L01EM04 encorafenib 0.45 g O L01EC03 entrectinib 0.6 g O L01EX14 erdafitinib 9 mg O L01EX16 erlotinib 0.15 g O L01EB02 esketamine 8 mg N N06AX27 everolimus 10 mg O L01EG02 fedratinib 0.4 g O L01EJ02 gefitinib 0.25 g O L01EB01 gemifloxacin 0.2 g P J01MA15

920 WHO Drug Information, Vol 34, No. 4, 2020 ATC/DDD Classification

gilteritinib 0.12 g O L01EX13 ibrutinib 0.42 g O L01EL01 idelalisib 0.3 g O L01EM01 imatinib 0.4 g O L01EA01 lapatinib 1.25 g O L01EH01 larotrectinib 0.2 g O L01EX12 lenvatinib 18 mg O L01EX08 lorlatinib 0.1 g O L01ED05 luspatercept 3.33 mg P B03XA06 midostaurin 0.1 g O L01EX10 mirogabalin 25 mg O N02BG11 neratinib 0.24 g O L01EH02 nilotinib 0.6 g O L01EA03 nintedanib 0.38 g O L01EX09 osimertinib 80 mg O L01EB04 ozanimod 0.92 mg O L04AA38 palbociclib 94 mg O L01EF01 pazopanib 0.8 g O L01EX03 pemigatinib 9 mg O L01EX20 perhexiline 0.2 g O C08EX02 pexidartinib 0.8 g O L01EX15 ponatinib 45 mg O L01EA05 pralsetinib 0.4 g O L01EX23 regorafenib 0.12 g O L01EX05 remdesivir 0.1 g P J05AB16 ribociclib 0.45 g O L01EF02 ripretinib 0.15 g O L01EX19 ruxolitinib 30 mg O L01EJ01 selpercatinib 0.32 g O L01EX22 semaglutide 10.5 mg O A10BJ06 sodium phosphate 8 g O V03AG05

921 ATC/DDD Classification WHO Drug Information, Vol 34, No. 4, 2020

sorafenib 0.8 g O L01EX02 sunitinib 33 mg O L01EX01 temsirolimus 3.57 mg P L01EG01 tivozanib 1 mg O L01EK03 trametinib 2 mg O L01EE01 tucatinib 0.6 g O L01EH03 vandetanib 0.3 g O L01EX04 velmanase alfa 10 mg P A16AB15 vemurafenib 1.92 g O L01EC01 zanamivir 1.2 g P J05AH01 zanubrutinib 0.32 g O L01EL03

WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2020

922